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Background and objective: The use of Symptomatic Slow-Acting Drugs in Osteoarthritis (SYSADOAs) may
be expected to decrease the use of concomitant medications for rescue analgesia, including non-steroidal
anti-inﬂammatory drugs (NSAIDs). The Pharmaco-Epidemiology of GonArthroSis (PEGASus) study was
designed to assess this possibility.
Methods: PEGASus was a cohort study of continuous recruitment of patients with “dynamic” exposure to
the investigated SYSADOA (crystalline glucosamine sulfate, glucosamine hydrochloride, chondroitin
sulfate, diacerein, and avocado–soybean unsaponiﬁables, all at approved dosages). Investigators were
rheumatologists or general practitioners randomly selected from French telephone lists. Patients
diagnosed with knee osteoarthritis (OA) were recruited when consulting an investigator for a symptom
ﬂare and were prescribed, or not, one of the SYSADOAs as per clinical judgment. Follow-up visits were as
per routine medical practice in the 12 months following enrollment, with telephone interviews after
1 month and at 4-month intervals thereafter up to 24 months. Use of NSAIDs was recorded, as well as the
dynamism of treatment exposure consisting of continuing the prescribed SYSADOA, switching, dis-
continuation or initiation of a SYSADOA. Patient exposure was expressed in 2-month time units, with any
NSAID use as Yes/No binary outcome during each unit. Odds ratios [OR and 95% conﬁdence interval (CI)]
of NSAID use were calculated for periods of exposure to each SYSADOA, by multivariate logistic
regression for an 80% power and 95% conﬁdence to see a decrease of at least 15%.
Results: This report consists of the full data pertaining to crystalline glucosamine sulfate, while results of
other SYSADOAs were summarized as available from the French Health Authority (HAS) website (www.
has-sante.fr). Of 6451 patients in the PEGASus cohort, 315 patients received crystalline glucosamine
sulfate, they were exposed for 481 2-month time units and had an incident use of NSAIDs of 18.7%. In the
control cohort (9237 time units) NSAID incident use was 23.8%. Crystalline glucosamine sulfate
signiﬁcantly decreased the risk of NSAID consumption by up to 36% (OR ¼ 0.64; 95% CI: 0.45–0.92) in
the primary analysis foreseen by the protocol; OR was 0.74 (95% CI: 0.54–1.01), i.e. at the very limit of
signiﬁcance, in a sensitivity analysis accounting for an extension of the study and of the control cohort.
None of the other SYSADOAs showed any hint of a decrease in the use of NSAIDs.
Conclusion: Crystalline glucosamine sulfate was the only SYSADOA that decreased the use of NSAIDs in
this pharmaco-epidemiology study in patients with knee OA.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r HS Journals, Inc. This is an open access article under the CC BY-NC-ND license
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Drugs for osteoarthritis (OA) are developed with the aim of
selectively controlling the symptoms of the disease (symptom-
modifying drugs) and/or the disease progression in term of joint
structure changes (structure-modifying or disease-modifying
drugs). In particular, targeted symptom-modifying drugs in OA
should be able to limit the consumption of unspeciﬁc symptomatic
medications, including pure analgesics and non-steroidal anti-
inﬂammatory drugs (NSAIDs). There is in fact general concern
regarding a possible overuse, especially of NSAIDs, given their poor
safety proﬁle on gastrointestinal, cardiovascular, renal, and other
systems [1].
Consumption of rescue medications including analgesics and/or
NSAIDs has been traditionally indicated as a possible ancillary
outcome in clinical trials of new symptom-modifying agents, e.g.,
in the 1996 Osteoarthritis Research Society International (OARSI)
guidelines [2]. However, such an outcome is difﬁcult to assess in
randomized controlled trials (RCTs), since it is prone to the
patient’s subjective response, with recourse to the rescue medi-
cation not necessarily linked to the severity of symptoms.
In addition, recent evidence suggests that allowing concomitant
symptomatic agents in RCTs of OA pain is associated with reduced
assay sensitivity [3]. The new OARSI guidelines for conducting
clinical trials in knee OA [4] actually no longer recommend rescue
medication use as a reliable study outcome and ideally suggest to
avoid the use of rescue analgesics in the trial to maximize the
treatment effect. On the other hand, the recommendations
acknowledge that this may adversely affect dropout and adherence
rates, therefore suggesting to carefully standardize the recourse to
rescue medications [4].
Symptomatic Slow Acting Drugs in OA (SYSADOAs), including
glucosamine sulfate, chondroitin sulfate, diacerein, and avocado–
soybean unsaponiﬁables (ASU), decrease OA symptoms with slow
onset of action, and may delay the progression of joint structure
changes along with symptom modiﬁcation (disease-modifying
effect), with different levels of evidence within the class [5]. Such
medications are given orally for prolonged treatment courses and
have the potential to decrease the use of drugs for rescue
analgesia, including NSAIDs [6]. However, for the reasons
described above, this effect was not well substantiated in clinical
studies that so far produced only hints for such an effect [7–9].
In fact, the main concern of sponsors and investigators, in agree-
ment with the recent OARSI recommendations [4], has always
been rather to standardize the recourse to the rescue medication
in order not to jeopardize the assay sensitivity. Such procedure
deliberately resulted in non-signiﬁcant differences with placebo in
rescue analgesia use, e.g., in the long-term trials of chondroitin or
glucosamine sulfate [10–12].
Pharmaco-epidemiology studies may be better suited than RCTs
to detect an effect of SYSADOAs on the use of rescue or concom-
itant symptomatic drugs, given the real-life situation and the lack
of constrictions imposed by RCTs. The Pharmaco-Epidemiology of
GonArthroSis (PEGASus) study was designed to assess the impact
of SYSADOAs on the use of NSAIDs.Methods
Context and study design
The PEGASus study was requested and authorized by the
French authorities for drug approval [Haute Autorité de Santé
(HAS)] and reimbursement (Transparency Commission) to assess
the impact of SYSADOAs on the use of NSAIDs in patients with
knee OA, in order to further assess the efﬁcacy of this drug classrelative to this parameter and to substantiate the public health
interest in the prevention of risks induced by NSAIDs. The study
was funded by the pharmaceutical companies marketing SYSA-
DOAs in France, but it was independently conducted and analyzed
by an independent research organization, under the supervision of
a Scientiﬁc Committee consisting of pharmacologists and two
rheumatologists. The industry sponsors were involved as observ-
ers only, providing scientiﬁc input in the design of the study
protocol and its amendments, as well as in the meetings of the
Scientiﬁc Committee; they did not participate in the study
performance, choice of investigators (whose list was not commu-
nicated to them), data collection, and statistical analysis.
The study protocol was approved by the relevant committees
for the protection of patients in France [Comité Consultatif sur le
traitement de l’information en matière de recherché dans le
domaine de la santé (CCTIRS) in November 2009 and Commission
Nationale de l’Informatique et des LIbertés (CNIL) in January 2010].
The protocol was amended with relevant approvals: in 2010 (prior
to the study beginning) to ﬁnalize the design as a continuous
cohort with “dynamic” exposure to prescribed treatments (see
below); in 2011 (maximum treatment duration extended from 9 to
24 months); and 2012 (from enrollment of a ﬁxed number of
patients per site to a “competitive” enrollment, to facilitate patient
recruitment).
PEGASus was designed as a cohort study of continuous recruit-
ment of patients with dynamic exposure to the investigated
treatments; “dynamism” constituted the registration of treatment
with the prescribed SYSADOA as a function of treatment contin-
uation, interruption and/or change in the SYSADOA prescribed.
This dynamism was taken into account in the analysis, which was
conducted by 2-month period of exposure (see below).
The following SYSADOAs (at approved dosages) were included
in the study: glucosamine sulfate (as the original preparation of
patented crystalline glucosamine sulfate), glucosamine hydro-
chloride, chondroitin sulfate, diacerein, and ASU. The methods
and results of the PEGASus study are published on the website of
the French Health Authority (HAS) (www.has-sante.fr). The
present report consists of the full data for crystalline glucosamine
sulfate, while the main results relevant to the other SYSADOAs are
summarized from publicly available material (www.has-sante.fr).
Patient selection and investigators
Adult patients of both genders diagnosed with knee OA (and/or,
to a lesser extent, hip OA for some of the investigated SYSADOAs)
were recruited when consulting an investigator [rheumatologist or
general practitioner (GP)] for a symptom ﬂare of their OA. Major
exclusions were patients receiving SYSADOAs for more than
3 months, or intra-articular hyaluronic acid in the last 3 months,
or suffering from any other form of arthritis, tendinitis of the lower
limbs, or radiculopathy. Patients were informed orally and in
writing about the aims and procedures of the study and signed
the informed consent form.
Investigators were randomly selected de novo from French
telephone lists.
Study procedures
On the enrollment visit, patients were screened for eligibility
according to the inclusion/exclusion criteria and the following
were recorded: socio-demographic characteristics and anamnestic
data, comorbidities, risk factors that may affect NSAID use, drugs
used over the past 3 months, and the SYSADOA prescribed (if any).
Follow-up visits occurred as required by standard medical practice
in the 12 months following enrollment, with a telephone interview
occurring after 1 month and at 4-month intervals (71 month)
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or clinic visit, the following were recorded: adverse events, use of
non-OA treatments and of treatments for OA, with start date and
other details (dose, reason for prescription, regular use or as
needed, and duration), including continuation of treatment with
the prescribed SYSADOA (if any), prescription switch to another
SYSADOA, discontinuation or start of treatment with a SYSADOA
(if not prescribed at enrollment). Symptoms of OA were collected
at enrollment and at follow-up visits/interviews by pain ordinal
scale (0–10 score) and by the Lequesne index (0–24 scale) [13] in
order to appropriately correct NSAID use data in the primary
statistical analysis (see below).
Treatments
The present report describes in details the characteristics and
the results of the cohort receiving oral crystalline glucosamine
sulfate in the original formulation as sachets of powder for oral
solution dosed as 1500 mg glucosamine sulfate (Osaﬂexans in
France, Donas or Viartril-Ss or other trademarks by the Rottapharm
group, Monza, Italy elsewhere), and corresponding to 1178 mg of
glucosamine. Crystalline glucosamine sulfate in this formulation is
approved as a prescription drug throughout Europe and in over 60
countries of the world, and it is available as a branded and
proprietary dietary supplement in the USA and other countries.
Other SYSADOAs evaluated in the PEGASus study were: Glucosamine hydrochloride two tablets, each corresponding to
625 mg (total 1250 mg) glucosamine, once daily Chondroitin sulfate 400 mg capsules or sachets, three
times daily Diacerein 50 mg capsules, twice daily
 ASU 300 mg capsules, once daily.
The results for the primary endpoint (see below) for these other
SYSADOAs were obtained from the publicly and freely available
reports from the French Health Authority website (HAS) (www.
has-sante.fr).
Statistical analysis
The primary analysis was conducted dividing the patient
exposure in the study into time units, each time unit correspond-
ing to a 2-month period. For each 2-month time unit in each
patient (patient-time unit) the analysis considered whether the
selected SYSADOA had been used (Yes/No) and whether there was
any recourse to any NSAID (Yes/No, regardless of type of NSAID,
dosage, treatment duration). The primary outcome was therefore
represented by the risk [odds ratio (OR) and 95% conﬁdence
interval (CI)] of using an NSAID in patient-time units while
receiving crystalline glucosamine sulfate or another SYSADOA, as
compared with patient-time units when not receiving any SYSA-
DOA. Such primary analysis was conducted by multivariate logistic
regression according to a generalized estimating equation (GEE)
model, adjusted for the following variables: gender, age (o60
years, 60–75 years, 475 years), pain score (o7 or Z7), number
of ﬂares (0, r2, 42), Lequesne index (o9/24 or Z9/24), OA
duration (r1 year or 41 year), education level (lower or equal/
higher than high school degree) recourse to physical treatments/
orthoses/prosthesis (Yes/No), risk factors for potentially limiting
NSAID use (history of cardiovascular or gastrointestinal disease,
renal insufﬁciency, and hypersensitivity), presence of other treat-
ments for OA including other SYSADOAs (Yes/No) or analgesics
(Yes/No).
Socio-demographic and other variables were analyzed by
descriptive statistics. The study was sized for each SYSADOA inorder to have an 80% power and 95% conﬁdence to see at least a
15% decrease in NSAID consumption risk. In particular, the crys-
talline glucosamine sulfate cohort was sized to detect an 18%
decrease in NSAID consumption risk, with an hypothesized 27%
rate of NSAID use in the control cohorts (consisting of 10,000
patient-time units, i.e., enough patients to provide 10,000 2-month
periods), resulting in the requirement of 500 patient-time units on
treatment with glucosamine sulfate.
The PEGASus study commenced in March 2010 for the SYSA-
DOAs traditionally available on the French market (chondroitin
sulfate, diacerein and ASU). Crystalline glucosamine sulfate and
other glucosamines began commercialization in France during
2010 and their inclusion in the PEGASus study could start
effectively in November 2010 at a reduced rate. As such, when
the study was closed for chondroitin sulfate, diacerein, and ASU in
October 2012, insufﬁcient patients necessary to reach the calcu-
lated sample size had been achieved in the glucosamine cohorts.
However, approximately 80% of the requested sample for crystal-
line glucosamine sulfate had been enrolled by October 2012 and
the study Scientiﬁc Committee decided not to amend the protocol
to modify the primary analysis which was forecasting the use of
data from the control cohort (no SYSADOA) until October 2012
only. Nevertheless, it was decided to extend the follow-up of the
original control cohort and to enroll a new control cohort from
October 2012, to be used in sensitivity analyses. The PEGASus
study was completed for glucosamines in April 2013. The primary
analysis was conducted on the control cohort until October 2012,
in agreement with the study protocol. A sensitivity analysis was
performed using also the new control cohort and the follow-up
period of the original control cohort after October 2012, until
completion of the study in April 2013. Finally, an additional and
partial analysis was included, modifying the main sensitivity in
that it censored the original control cohort data generated after
October 2012 and it was thus scarcely applicable as a sensitivity
analysis.
The primary analysis foreseen by the protocol was also per-
formed on ancillary outcomes, i.e., considering only patients who
had been on glucosamine sulfate for at least 4 months, or taking
into account a 2-month carryover effect after drug withdrawal;
both are typical features of a SYSADOA [6].Results
Participating physicians and patient population
The ﬂowchart of physician selection and patient inclusion is
depicted in Figure 1. A total of 38,014 GPs were randomly
contacted, in addition to all private practice rheumatologists in
France; 4052 physicians accepted to participate, and 745 physi-
cians (642 GPs and 96 rheumatologists) included at least one
patient in the study.
Overall, the PEGASus cohort recruited 6451 patients. Figure 2
reports the cumulative enrollment of patients throughout the
study. Over 50%, i.e., 3725 patients completed the study interview
at 12 months and 1154 at 24 months. A total of 315 patients
received crystalline glucosamine sulfate during the study (Fig. 3),
with an average follow-up of 10 months in the cohort. They
contributed a total of 962 patient-months, i.e., 481 2-month time
units, for the analysis of the primary endpoint.
Patients participating in the PEGASus cohort (N ¼ 6451) had a
mean age of 66 years, were overweight (mean BMI ¼ 28), and 63%
were women. Almost half of the patients had OA at multiple joints
and lower limb OA was of moderate severity, with average 0–10
pain score of 5.6 points and severe handicap on the Lequesne
index in 65% of patients. These data are described in Table 1,
France  Telecom Lists of GPs and Rheumatologists
Random sampling of Participating Physicians
Inclusion of patients with knee or hip osteoarthritis and pain
PEGASus COHORT
Patients with 
SYSADOA1 @ entry
Patients with 
SYSADOA2 @entry
Patients with 
SYSADOA3 @ entry
Patients with 
No-SYSADOA @ entry
Population-time accumulated for each individual SYSADOA+
Population-time without any SYSADOA
Assignment of treatments @ Entry 
SYSADOA switching, continuation, discontinuation, or start during follow-up
Fig. 1. Flowchart of physician selection and patient inclusion in the PEGASus study.
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excluding the 315 patients receiving crystalline glucosamine
sulfate (N ¼ 6136), in the crystalline glucosamine sulfate cohort
(N ¼ 315) and in the subcohort (within the 6136 patients) who
received no SYSADOAs during the study and thus contributed to
the majority of control patient-months and time units.
While there were no differences in the main demographic
characteristics and disease severity, it appears that patients
receiving crystalline glucosamine sulfate had a slightly shorter
disease duration at enrollment and had a higher school educa-
tion than the overall cohort, especially compared with patientsFig. 2. Cumulative patient recruitment in thenever receiving a SYSADOA. Patients on glucosamine sulfate had
also a history of slightly more allergies to NSAIDs, but also less risk
factors such as cardiovascular, gastrointestinal, or urinary tract
diseases.Primary outcome for the crystalline glucosamine sulfate cohort
The 315 patients prescribed crystalline glucosamine sulfate con-
tributed 962 patient-months to the primary analysis, corresponding
to 481 2-month time units. Conversely, the control cohort time unitsPEGASus complete cohort (N ¼ 6451).
Fig. 3. Cumulative patient recruitment in the crystalline glucosamine sulfate cohort in the PEGASus study (N ¼ 315).
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9237 time units. The results of the primary outcome are reported in
Table 2.
In the control cohort there was an incident use of NSAIDs of
23.8% in the primary analysis, compared with 18.7% in the
crystalline glucosamine sulfate cohort, i.e., a signiﬁcant decrease
in risk of 36% (OR ¼ 0.64; 95% CI: 0.45–0.92). The sensitivity
analysis accounting for the inclusion of new control patients and
extending the follow-up of the original control cohort after
October 2012, provided a similar result with an OR of 0.74 (95%
CI: 0.54–1.01). The partial additional analysis provided a result in
the same direction, but with wider conﬁdence interval (data not
shown).
In the primary analysis foreseen by the protocol, when only
patients receiving glucosamine sulfate for more than 4 months
were considered as a secondary outcome (420 patient-months)Table 1
Patient characteristics in the entire PEGASus cohort at enrollment (N ¼ 6451), div
who received crystalline glucosamine sulfate. The characteristics of the subcohort of pa
Patients who received no crystalline
glucosamine sulfate (N ¼ 6136)
Age (years) 66.3 7 12.0
Women, % 63.5
BMI 28.0 7 5.0
OA duration (if reported), %
o1 year 25.7
1–5 years 41.8
45 years 31.0
Pain scale 5.6 7 1.8
Lequesne index classiﬁcation, %
Mild/moderate (r7 points)
Severe (Z8 points)
35.2
64.8
Physical therapy, % 11.8
Orthosis, % 11.9
Prosthesis, % 5.6
High school degree or higher, % 37.8
Allergy to NSAIDs, % 2.3
History of
cardiovascular disease, % 57.6
gastrointestinal disease, % 23.4
genito-urinary disease, % 8.1
other OA joint localizations, % 42.6the decrease in risk was 48% and signiﬁcant (OR ¼ 0.52; 95% CI:
0.28–0.95), with an incident NSAID use of 16.2%.
Another secondary outcome consisted of the analysis performed
including a 2-month carryover effect after crystalline glucosamine
sulfate treatment withdrawal: the decrease in the risk of use of
NSAIDs was signiﬁcant (OR ¼ 0.68; 95% CI: 0.47–0.96), with
an incident NSAID use of 18.7%, although the analysis could
be performed only in a small additional number of patients
corresponding to 984 patient-months, i.e., 492 2-month time units.Primary outcome for all other SYSADOAs cohorts
Figure 4 depicts the results for the primary outcome of the
PEGASus study, as retrieved from the French Health Authority
(HAS) website (www.has-sante.fr).ided into patients who received no crystalline glucosamine sulfate and those
tients who received no SYSADOA are also reported
Patients who received crystalline
glucosamine sulfate (N ¼ 315)
Patients who received no
SYSADOA (N ¼ 1376)
64.4 7 12.0 69.1 7 11.9
66.7 64.1
27.4 7 4.9 28.2 7 5.1
25.5 21.7
43.9 40.2
27.1 37.7
5.5 7 1.8 5.5 7 1.7
35.4 35.3
64.6 64.7
11.1 10.9
8.0 15.3
4.4 8.7
48.1 30.7
3.2 2.4
49.5 63.6
20.4 25.0
7.6 9.5
45.7 42.9
Table 2
Risk (odds ratio and 95% CI) of NSAID use with crystalline glucosamine sulfate
compared with controls in the PEGASus study: primary and sensitivity analysis
Time
unitsa
NSAID
use (%)
Odds ratio
(95% CI)
Primary analysis
Control cohort 9237 23.8% 1
Crystalline glucosamine
sulfate cohort
481 18.7% 0.64 (0.45–0.92)
Sensitivity analysis
Control cohort 15,756 21.6% 1
Crystalline glucosamine
sulfate cohort
481 18.7% 0.74 (0. 54–1.01)
a Each time unit corresponds to a two-month observation period.
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ent effect compared with crystalline glucosamine sulfate, since it
had no effect on NSAID use in the PEGASus cohort in the primary
analysis (OR ¼ 0.98; 95% CI: 0.81–1.19) or in the glucosamine
cohort sensitivity analysis (OR ¼ 1.09; 95% CI: 0.91–1.29). The
same was true for all other SYSADOAs: neither chondroitin sulfate
(OR ¼ 0.94; 95% CI: 0.77–1.14), ASU (OR ¼ 0.98; 95% CI: 0.82–1.17),
nor diacerein (OR ¼ 1.08; 95% CI: 0.87–1.33) decreased NSAID
consumption in the primary analysis of the PEGASus study.Discussion
Glucosamine sulfate, in the original formulation of prescription
crystalline glucosamine sulfate 1500 mg once daily, decreased the
use of NSAIDs in patients with knee OA in the Pharmaco-
Epidemiology of GonArthroSis (PEGASus) study. Interestingly,
glucosamine hydrochloride at a similar glucosamine daily dose
was not able to attain a similar effect and other SYSADOAs, namely
chondroitin sulfate, diacerein, and ASU at their usually prescribed
doses, were also not able to decrease NSAID use in the PEGASus
cohort.
SYSADOAs were developed as targeted medications for OA to be
safer than, and at least as effective as, non-speciﬁc symptomatic
medications such as pure analgesics and NSAIDs, able to control
symptoms over long-term treatment courses with the added0.4 0.6
Glucosamine sulfate
(primary analysis)
Glucosamine sulfate
(sensitivity analysis)
Glucosamine hydrochloride
(primary analysis)
Glucosamine hydrochloride
(sensitivity analysis)
Chondroitin sulfate
Avocado soybean unsaponifiables
Diacerein
0.640.45
0.54
Fig. 4. Odds ratio (with 95% CI) of NSAID usbeneﬁt of possible joint structure modiﬁcation, and therefore
disease modiﬁcation [6]. In theory, SYSADOAs should also be able
to decrease the consumption of NSAIDs for prolonged symptom
control and/or for OA ﬂares. This is a difﬁcult outcome to assess in
RCTs, given the often subjective NSAID use and the limitations
imposed in rigorous studies by the standardization of rescue
medications. Indeed, evidence for such an effect of SYSADOAs is
limited in the scientiﬁc literature. In the 6-month GUIDE study of
crystalline glucosamine sulfate vs. placebo and vs. paracetamol [7],
the former decreased the proportion of patients using rescue
NSAIDs compared with placebo and also reduced the number of
days of use. However, this was only an additional analysis, and not
the primary or secondary outcome in this rigorous pivotal trial
with careful standardization of the rescue medication [7].
In another 6-month RCT, NSAID consumption was slightly lower
with ASU than with placebo and fewer patients on ASU required
NSAIDs [8]. Similarly, long-term users of chondroitin sulfate had
lower use of NSAIDs or analgesics in a cross-sectional observa-
tional survey [9]; analogous evidence is scarce for diacerein. The
PEGASus study was designed to conﬁrm and expand such evidence
with a pharmaco-epidemiology approach, which is probably more
suitable than an RCT to assess this outcome given the real-life
situation. Indeed, the PEGASus cohort was recruited from the
standard clinical practice of 745 randomly selected GPs or rheu-
matologists, from their patients consulting for a lower limb painful
OA ﬂare. Patients (and physicians) could modify their treatment as
in real-life, e.g., stop the prescribed SYSADOA, shift to another
SYSADOA, continue or start one or another for a follow-up of up to
24 months, with scheduled interviews to record the main treat-
ment data and risk factors that may affect them. All information
was taken into account in the statistical analysis, that was
organized in 2-month time units with a binary outcome (NSAID
use: Yes/No).
Glucosamine sulfate given as the patented crystalline glucos-
amine sulfate formulation [14] decreased the risk of using NSAIDs
by up to 36%. The study had an 80% power to see an 18% decrease
in NSAID consumption risk with a hypothesized 27% rate of NSAID
use in the control cohort and 500 time units on glucosamine
sulfate. Given the time constraints imposed by the French Health
Authority to receive the study data, there were 481 time units
for the 315 patients in the glucosamine sulfate cohort, close to
the postulated 500 time units. Despite the slightly lower
than hypothesized recourse to NSAIDs in the control cohort,Odds Ratio (OR) NSAID
0.8 1.0 1.2 1.4
0.92
0.74 1.01
0.98 1.190.81
1.09 1.290.91
0.94 1.140.77
1.08 1.330.87
0.98 1.170.82
Odds ratio (and 95% CI) use
e with SYSADOAs in the PEGASus study.
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cally signiﬁcant and clinically relevant in the primary analysis
foreseen by the protocol. Since the glucosamine cohorts entered
the PEGASus study later than other SYSADOAs and the stipulated
number of patients had not been reached by study end, it was
necessary to prolong the observation period of the original control
cohort. An additional control cohort was also started and used in a
sensitivity analysis that included all reference time in the different
control cohorts. The results were in the same direction, with a
decrease in risk of 26% that was at the very limit of statistical
signiﬁcance (upper 95% conﬁdence limit: 1.01) probably because of
the further slight decrease in NSAID use, 21.6%, in the prolonged
control cohort. On the other hand, the signiﬁcant results of the
protocol primary analysis are reliable, because approximately 80%
of glucosamine sulfate patients had already been recruited when
the original control cohort foreseen by the protocol primary
analysis was extended, and a new control cohort started with
the aim of performing the sensitivity analysis.
In secondary analyses, the decrease in risk was even higher
(52%) when glucosamine sulfate was used for longer than
4 months. The effect was still signiﬁcant when a 2-month carry-
over effect, a typical feature of SYSADOAs [6], was included in the
analysis.
This present report is devoted to the full results obtained with
crystalline glucosamine sulfate. Reporting the detailed data for
each SYSADOA tested in the PEGASus study falls outside the
scope of this article. Results for all other compounds tested are
publicly accessible on the French Health Authority (HAS) website
(www.has-sante.fr) and the data of the primary analysis are
summarized here. In this respect, it is ﬁrst of all interesting to
note that glucosamine hydrochloride was not able to decrease
NSAID consumption. Glucosamine hydrochloride is widely used as
a dietary supplement as it is unpatented, readily available, easy to
handle, inexpensive, and, unfortunately, it has been approved by
some health authorities as an over-the-counter (OTC) medication
or a generic of crystalline glucosamine sulfate. Actually, in our
opinion this is completely inappropriate, since glucosamine hydro-
chloride has never been shown to be effective in knee OA, which is
quite the opposite for glucosamine sulfate, as nicely described in a
meta-analysis by OARSI within one of its treatment guidelines
documents [15]. Glucosamine hydrochloride was not found effec-
tive even in selected large and rigorous clinical trials such as the
NIH-sponsored GAIT (Glucosamine/chondroitin Arthritis Interven-
tion Trial) study [16]. Indeed, glucosamine hydrochloride has a
different pharmacokinetic proﬁle than crystalline glucosamine
sulfate, resulting in a 50–75% decrease in bioavailability when
given at standard doses and formulations [17]. Therefore, the data
from PEGASus support what is already known from the literature.
It is more difﬁcult to interpret the lack of effect in decreasing
NSAID consumption found with other SYSADOAs. The recent
European Society for Clinical and Economic Aspects of Osteopo-
rosis and Osteoarthritis (ESCEO) algorithm recommendations for
knee OA [5] advise that only the prescription formulations of
glucosamine sulfate (i.e., the patented crystalline glucosamine
sulfate described here) or chondroitin sulfate should be used in
the ﬁrst step of treatment as long-term pharmacological back-
ground, since the evidence is scarce for other SYSADOAs such as
ASU or diacerein. More data are therefore needed for chondroitin
sulfate in order to attain a similar level of evidence shown in
PEGASus for crystalline glucosamine sulfate with respect to a
sparing effect on rescue NSAID use.
As already discussed in the reports of crystalline glucosamine
sulfate pivotal trials [7,11,12], it is unlikely that the data obtained
here can be transferred to OTCs or generics claiming the use of
other supposed glucosamine sulfate formulations. These formula-
tions may indeed be unstable and lose most of their label contentin glucosamine [18], since they are not using the same patented
method of stabilization of crystalline glucosamine sulfate [14] and
may even have a different pharmacokinetic and pharmacological
proﬁle [17]. It is well known that there are no favorable trials of
glucosamine sulfate other than those with crystalline glucosamine
sulfate. In fact, the latest edition of the glucosamine Cochrane
Review failed to show any efﬁcacy on pain of these other
formulations (including glucosamine hydrochloride) in high-
quality trials [19], while the efﬁcacy is statistically signiﬁcant
when the three high-quality pivotal trials of crystalline glucos-
amine sulfate are pooled [19] and the effect size is clinically
relevant as also shown in other recent meta-analyses [20,21].
The prescription formulation of crystalline glucosamine sulfate is
recommended by the European guidelines [22] and in the recent
ESCEO algorithm recommendations [5], while glucosamine’s role
is described as uncertain in the American College of Rheumatology
(ACR) or OARSI guidelines [23,24], given the lack of prescription
products in the US in the former [23] and the authors’ decision not
to differentiate between the different glucosamine formulations in
the latter [24], contrary to previous OARSI guideline documents
[15].Conclusion
The patented formulation of prescription crystalline glucos-
amine sulfate was the only SYSADOA able to decrease rescue
NSAID use in the PEGASus study. These data further conﬁrm the
unique efﬁcacy of this crystalline glucosamine sulfate formulation
in the management of knee OA.
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